Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 2/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20152044 | 0.85 | HRH3 (0.58) | PDE9APDE10AHRH3 | |
| SCHEMBL2582495 | 0.83 | PDE10A (0.44) | PDE10APOLBGAASLC6A4 | |
| SCHEMBL20068827 | 0.78 | SSTR4 (0.44) | PDE9AHRH3SLC6A4 | |
| SCHEMBL23761235 | 0.77 | EPHX2 (0.44) | PDE10APOLBGAA | |
| SCHEMBL30505244 | 0.77 | EPHX2 (0.44) | PDE10APOLBGAA | |
| SCHEMBL20070185 | 0.76 | HSD11B1 (0.48) | SLC6A4 | |
| SCHEMBL25807458 | 0.76 | SLC6A4 (0.47) | HRH3SLC6A4 | |
| SCHEMBL20147891 | 0.76 | PDE10A (0.39) | PDE10APOLBGAA | |
| Hydrochloric Acid SCHEMBL25401967 | 0.75 | EPHX2 (0.44) | PDE10APOLBGAA | |
| SCHEMBL3130466 | 0.74 | HRH3 (0.55) | PDE10AHRH3MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | PDE9A 1154/4885PDE10A 929/4885HRH3 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.